Consequently,
New delay supply medicines based:
The Viatris laboratory has informed the National Medicines Safety Agency (ANSM) that. Nevertheless, contrary to what was planned, it is not able to supply the pharmacies with Quetiapine 300 mg LP and 400 mg LP. In addition, This is due to the difficulties encountered by the pharmathen production site of the drug. Consequently, As a result, tensions on their availability should persist until mid-September. Consequently, ANSM has published a communiqué to focus on this situation.
Although the Quetiapine 50 mg LP Viatris is not affected by this delay. Meanwhile, the agency asks ” Doctors and pharmacists do not postpone prescriptions and dispensations on Quetiapine LP 50 mg for patients not using this dosage usually ». It is a question of guaranteeing its availability for the usual needs.
The ANSM is looking for new delay supply medicines based alternative supply solutions with laboratories marketing Quétiapine in France and Europe. She asked them to “ release all of their stocks now Until the Viatris Laboratory is replenished.
Masterful preparation – New delay supply medicines based
The agency recalls the measures taken previouslywhich remain topical. This is in particular the possibility for pharmacists of ” Replace Quetiapine -based drugs in prolonged release with capsules in immediate release of 50 mg. 100 mg and/or 150 mg ». This masterful preparation system must be implemented on the basis of the ANSM recommendations. Stability studies have made it possible to pass the conservation time of capsules prepared at 12 weeks, against 6 weeks earlier. This should allow pharmacists ” to better anticipate the production of preparations and to organize more effectively if necessary ».
Unit dispensation
It is new delay supply medicines based also possible to provide Quetiapine -unit -based drugs. including for 300 and 400 mg dosages, ” in accordance with medical prescription and within the limits of a month of treatment ». This allows pharmacists ” to adapt the quantities delivered to the real needs of patients. especially in the event of initiation or titration or when the boxes contain a large number of tablets ».
Suspension of treatment initiations
Finally. the agency asks practitioners to suspend treatment initiations, ” Except for patients with a depressed episode characterized as part of a bipolar disorder ». She offers a List of therapeutic alternatives depending on the clinical situation.
Further reading: What drugs GLP-1 have the most side effects? The study of 60,000 Facebook publications gives answers – Here is what to avoid doing so as not to have dry eyes this summer according to an ophthalmologist – Trumenba now reimbursed for 15-24 year olds – 1 million Tunisians affected by migraine, the CNAM does not recognize the disease – the press of Tunisia – Sickle cell anemia: major advances in screening and treatments.
